---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-232539"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2025-10-07T23:59:59+00:00"
generated_at: "2026-05-17T04:27:52.292194+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio: 100% renal response in Phase 1 ADI-001 lupus nephritis; plans FDA meeting Q1 2026

## Summary
- Seven patients (5 LN, 2 SLE) dosed; follow-up 2–9 months as of Aug 31, 2025 cut-off.
- All 5 LN patients achieved renal response: 3 complete, 2 partial; all ongoing; 3 also DORIS remission.
- No serious AEs, no ICANS; only Grade 1 CRS (2 patients) and 1 Grade 1 infection; outpatient potential.
- All patients discontinued immunosuppressants; discontinued or tapered corticosteroids to physiological levels.
- Plans to request FDA meeting in Q1 2026 for pivotal Phase 2 trial design; enrollment continues until study opens.

## SEC filing metadata
- accession: 0001193125-25-232539
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2025-10-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000119312525232539/0001193125-25-232539-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000119312525232539/acet-20251007.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-232539
- JSON: https://secwatch.observer/filing/0001193125-25-232539.json
- Plain text: https://secwatch.observer/filing/0001193125-25-232539.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.